IMCR earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -94.93. Updated 2026-07-23.
Immunocore Holdings (IMCR) Research Hub
Immunocore Holdings (IMCR) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 32.6 USD (-5.43%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -94.93, market cap 1.74B. This hub links to the full technical, earnings and options research available for IMCR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 32.6 USD (-5.43%) |
| 52-week range | 28.03 USD – 37.66 USD |
| Trend regime | Range |
| 14-day RSI | 43.1 (Bearish) |
| Trailing P/E | -94.93 |
| Market cap | 1.74B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for IMCR
Covered Call on IMCR: how it works, illustrative setup around the real 32.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IMCR: how it works, illustrative setup around the real 32.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IMCR: how it works, illustrative setup around the real 32.6 USD price, max profit/loss, breakeven and when to use it. Educational.
IMCR technical analysis: range, last 32.6 USD, RSI 43.1, 52w range 28.03 USD–37.66 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IMCR in?
Immunocore Holdings (IMCR) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is IMCR in an uptrend or downtrend?
As of 2026-09-11, IMCR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IMCR's trailing P/E ratio?
IMCR's trailing P/E is -94.93, with a market cap of 1.74B. See the earnings research page for full valuation detail.
When does IMCR next report earnings?
IMCR is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.01 USD.